Adding value to our partners' projects

We work closely with our partners’ scientific and administrative staff to:

– identify promising research results and ideas and secure appropriate intellectual property protection,
– develop projects to attain technology readiness levels that are attractive to investors and industry and,
– market and commercialize projects through licensing, cooperations and spin-offs.

Beyond this, we usually remain involved to monitor contract compliance, support spin-off growth and manage equity. Moreover, we create dedicated funding instruments, marketing platforms, and networking events for our partners.

Specialized in life sciences

Founded in 2001 as a 100% subsidiary of the LifeScience Foundation for the Promotion of Science and Research, Ascenion today supports 28 research organizations across Germany in all aspects of technology transfer. Ascenion’s partners include life-science institutions of the Helmholtz and Leibniz Associations, university hospitals and research centers. 10 of these endow to the LifeScience Foundation.

Focused on social impact

Our shared goal is to maximize the social and economic benefit of life-science research by bringing companies, services and products to market that have the potential to change our lives: for instance, new cancer treatments, environmentally friendly processes or innovative imaging techniques.

3 Valuable products and jobs in growth sector

Several products and spin-offs based on our partners’ research results have already reached the market, with many more on the way. Most recent successes are:

– BLINCYTO®, a new cancer drug (Max Delbrück Center for Molecular Medicine)
– VONVENDI [von Willebrand factor (recombinant)], treatment of bleeding disorder (Max Delbrück Center for Molecular Medicine)
– Akita®, a smart inhalation device (Helmholtz Zentrum München)
– Diagnostic test for the detection of JC Virus (Deutsches Primatenzentrum)
– Trianta Immunotherapies, spin-off acquired by Medigene: development of immunotherapies for the treatment of cancer (Helmholtz Zentrum München)

4 Benefits to society

As a wholly-owned subsidiary of the LifeScience Foundation for the Promotion of Science and Research, Ascenion acts on behalf of inventors, their institutes, and the society. The proceeds from commercialization and other revenues generated by Ascenion are reinvested in publicly funded research.

Close to our partners

With offices in Munich, Neuherberg, Berlin, Braunschweig, Hamburg and Hanover, our technology managers stay in close contact with the staff at our partner institutes.
Adding value to our partners’ projects
We work closely with our partners’ scientific and administrative staff to
– identify promising research results and ideas and secure appropriate intellectual property protection,
– develop projects to attain technology readiness levels that are attractive to investors and industry and,
– market and commercialize projects through licensing, cooperations and spin-offs.

Beyond this, we usually remain involved to monitor contract compliance, support spin-off growth and manage equity. Moreover, we create dedicated funding instruments, marketing platforms, and networking events for our partners.

Focused on social impact
Our shared goal is to maximize the social and economic benefit of life-science research by bringing companies, services and products to market that have the potential to change our lives: for instance, new cancer treatments, environmentally friendly processes or innovative imaging techniques.

Valuable products and jobs in growth sector
Several products and spin-offs based on our partners’ research results have already reached the market, with many more on the way. Most recent successes are:
– BLINCYTO®, a new cancer drug (Max Delbrück Center for Molecular Medicine)
– VONVENDI [von Willebrand factor (Recombinant)], treatment of bleeding disorder (Max Delbrück Center for Molecular Medicine)
– Akita®, a smart inhalation device (Helmholtz Zentrum München)
– Diagnostic test for the detection of JC Virus (Deutsches Primatenzentrum)
– Trianta Immunotherapies, spin-off acquired by Medigene: development of immunotherapies for the treatment of cancer (Helmholtz Zentrum München)

Returns for public research
As a wholly-owned subsidiary of the LifeScience Foundation for the Promotion of Science and Research, Ascenion acts on behalf of inventors, their institutes, and the society. The proceeds from commercialization and other revenues generated by Ascenion are reinvested in publicly funded research.

Close to our partners
With offices in Munich, Neuherberg, Berlin, Braunschweig, Hamburg and Hanover, our technology managers stay in close contact with the staff at our partner institutes.

Ascenion GmbH
Herzogstraße 64
80803 Munich, Germany
T +49 89 318814-0
info@ascenion.de
www.ascenion.de
**Ascenion at a Glance**

**IDENTIFY & SECURE**

commercially attractive results

- 700 technologies and materials
- 350 patent families: therapeutics, diagnostics, platforms, other 350 materials: antibodies, vectors, animal models
- 100 invention disclosures p.a.
- 60 patent applications p.a.

**COMMERCIALISE**

via licensing, cooperation or spin-off

- EUR 93.9 million revenues for our partner institutes*
- EUR 81.2 million return from agreements mediated by Ascenion
- EUR 12.7 million Ascenion's payouts to the LifeScience Foundation, mainly from exit proceeds
- 100 spin-offs supported, equity in 48 thereof*
- >1,000 revenue-carrying agreements with industry*
- 1,500 contacts to industry and investors

*since Ascenion's foundation in 2001

**RESEARCH**

- 5,000 scientists supported by Ascenion
- 28 partner institutions, 10 of them endow to the LifeScience Foundation: institutes in the Helmholtz and Leibniz Associations, Charité-Universitätsmedizin Berlin, Hannover Medical School, other university hospitals, research centres and further partners

**APPLICATION**

- 18 products on the market
- 32 products under development*
- 300 jobs in new companies

*preclinical or advanced

**DEVELOP**

to the inflection point of investment

- 10 Ascenion employees with dedicated project development expertise from industry
- 5-10 projects in development at any one time

- EUR 3.1 million p.a. in translational funding

- 5,000 scientists supported by Ascenion
- 28 partner institutions, 10 of them endow to the LifeScience Foundation: institutes in the Helmholtz and Leibniz Associations, Charité-Universitätsmedizin Berlin, Hannover Medical School, other university hospitals, research centres and further partners

- 18 products on the market
- 32 products under development*
- 300 jobs in new companies

*preclinical or advanced

**COMMERCIALISE**

via licensing, cooperation or spin-off

- EUR 93.9 million revenues for our partner institutes*
- EUR 81.2 million return from agreements mediated by Ascenion
- EUR 12.7 million Ascenion's payouts to the LifeScience Foundation, mainly from exit proceeds
- 100 spin-offs supported, equity in 48 thereof*
- >1,000 revenue-carrying agreements with industry*
- 1,500 contacts to industry and investors

*since Ascenion's foundation in 2001

**IDENTIFY & SECURE**

commercially attractive results

- 700 technologies and materials
- 350 patent families: therapeutics, diagnostics, platforms, other 350 materials: antibodies, vectors, animal models
- 100 invention disclosures p.a.
- 60 patent applications p.a.

**COMMERCIALISE**

via licensing, cooperation or spin-off

- EUR 93.9 million revenues for our partner institutes*
- EUR 81.2 million return from agreements mediated by Ascenion
- EUR 12.7 million Ascenion's payouts to the LifeScience Foundation, mainly from exit proceeds
- 100 spin-offs supported, equity in 48 thereof*
- >1,000 revenue-carrying agreements with industry*
- 1,500 contacts to industry and investors

*since Ascenion's foundation in 2001

**RESEARCH**

- 5,000 scientists supported by Ascenion
- 28 partner institutions, 10 of them endow to the LifeScience Foundation: institutes in the Helmholtz and Leibniz Associations, Charité-Universitätsmedizin Berlin, Hannover Medical School, other university hospitals, research centres and further partners

**APPLICATION**

- 18 products on the market
- 32 products under development*
- 300 jobs in new companies

*preclinical or advanced

**DEVELOP**

to the inflection point of investment

- 10 Ascenion employees with dedicated project development expertise from industry
- 5-10 projects in development at any one time

- EUR 3.1 million p.a. in translational funding

- 5,000 scientists supported by Ascenion
- 28 partner institutions, 10 of them endow to the LifeScience Foundation: institutes in the Helmholtz and Leibniz Associations, Charité-Universitätsmedizin Berlin, Hannover Medical School, other university hospitals, research centres and further partners

- 18 products on the market
- 32 products under development*
- 300 jobs in new companies

*preclinical or advanced

**COMMERCIALISE**

via licensing, cooperation or spin-off

- EUR 93.9 million revenues for our partner institutes*
- EUR 81.2 million return from agreements mediated by Ascenion
- EUR 12.7 million Ascenion's payouts to the LifeScience Foundation, mainly from exit proceeds
- 100 spin-offs supported, equity in 48 thereof*
- >1,000 revenue-carrying agreements with industry*
- 1,500 contacts to industry and investors

*since Ascenion's foundation in 2001

**IDENTIFY & SECURE**

commercially attractive results

- 700 technologies and materials
- 350 patent families: therapeutics, diagnostics, platforms, other 350 materials: antibodies, vectors, animal models
- 100 invention disclosures p.a.
- 60 patent applications p.a.

**COMMERCIALISE**

via licensing, cooperation or spin-off

- EUR 93.9 million revenues for our partner institutes*
- EUR 81.2 million return from agreements mediated by Ascenion
- EUR 12.7 million Ascenion's payouts to the LifeScience Foundation, mainly from exit proceeds
- 100 spin-offs supported, equity in 48 thereof*
- >1,000 revenue-carrying agreements with industry*
- 1,500 contacts to industry and investors

*since Ascenion's foundation in 2001

**RESEARCH**

- 5,000 scientists supported by Ascenion
- 28 partner institutions, 10 of them endow to the LifeScience Foundation: institutes in the Helmholtz and Leibniz Associations, Charité-Universitätsmedizin Berlin, Hannover Medical School, other university hospitals, research centres and further partners

**APPLICATION**

- 18 products on the market
- 32 products under development*
- 300 jobs in new companies

*preclinical or advanced

**DEVELOP**

to the inflection point of investment

- 10 Ascenion employees with dedicated project development expertise from industry
- 5-10 projects in development at any one time

- EUR 3.1 million p.a. in translational funding

- 5,000 scientists supported by Ascenion
- 28 partner institutions, 10 of them endow to the LifeScience Foundation: institutes in the Helmholtz and Leibniz Associations, Charité-Universitätsmedizin Berlin, Hannover Medical School, other university hospitals, research centres and further partners

- 18 products on the market
- 32 products under development*
- 300 jobs in new companies

*preclinical or advanced